Intervention not reported
Failure to achieve clinical response (100‐point response) · Patients with active Crohn's disease
The intervention leads to lower failure to achieve clinical response (100‐point response) (high certainty).
1 finding from 1 review
Intervention not reported
Endoscopic response · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life (QoL) Inflammatory Bowel Disease Questionnaire (IBDQ) (scale: 32 to 224; higher score = better QoL) · Patients with active Crohn's disease
1 finding from 1 review
Intervention not reported
Adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in serious adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Withdrawals due to adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in withdrawals due to adverse events (low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Certolizumab pegol probably leads to higher clinical remission compared with placebo (moderate certainty).
1 finding from 1 review
Clinical response · Patients with active Crohn's disease
Certolizumab pegol probably leads to higher clinical response compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Certolizumab pegol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults with severe acute pancreatitis
1 finding from 1 review
Length of hospital stay · adults with severe acute pancreatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital costs · adults with severe acute pancreatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults with severe acute pancreatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults with severe acute pancreatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of ICU stay · adults with severe acute pancreatitis
It is very uncertain whether continuous veno‐venous hemofiltration (CVVH) changes length of ICU stay compared with no CVVH (very low certainty).
1 finding from 1 review
Length of hospital stay · adults with severe acute pancreatitis
It is very uncertain whether continuous veno‐venous hemofiltration (CVVH) changes length of hospital stay compared with no CVVH (very low certainty).
1 finding from 1 review
Hospital costs · adults with severe acute pancreatitis
It is very uncertain whether continuous veno‐venous hemofiltration (CVVH) changes total hospital cost compared with no CVVH (very low certainty).
1 finding from 1 review
Quality of life · adults with severe acute pancreatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · adults with severe acute pancreatitis
High‐volume continuous veno‐venous hemofiltration (CVVH) showed no clear difference in all‐cause mortality compared with standard CVVH (low certainty).
1 finding from 1 review
Adverse events · adults with severe acute pancreatitis
It is very uncertain whether high‐volume continuous veno‐venous hemofiltration (CVVH) changes adverse events compared with standard CVVH (very low certainty).
1 finding from 1 review